Pharmaceutical Executive-11-01-2006

Pharmaceutical Executive

Back Page: The Case for Diversity

November 01, 2006

Column

0

0

When novartis had a look at its recent M&A activity, it found something unsettling: 70 percent of the deals it had done between 1996 and 2004 hadn't delivered their expected value to shareholders. Many other Big Pharmas are saddled with the same problem: The traditional pharmaceutical business model, by which prescription drug makers scoop up assets or companies similar to their own, is going nowhere fast.

Opinion: AARPeeved

November 01, 2006

Opinion

0

0

Critics of the pharma industry have gotten good at selective reporting. So good, I've started tuning out. But, with a public official pulling similar punches, my ears can't help but perk up.

Thoughtleader: Martin Mattingly, Ambrx

November 01, 2006

Thought Leader

0

0

The ability to customize small molecules-to make them better, safer, and easier to use-has long been a staple of pharmaceutical development. But until recently, scientists had few options for enhancing biologics. San Diego-based Ambrx wants to change that.

Roundtable: Deficit Reduction Act

November 01, 2006

Features

0

0

The Deficit Reduction Act was designed to save the government money on Medicaid. But it also has the potential to change the very way pharma companies conduct business-if they can just figure it out.

Alternative Media: Time to Change the Channel

November 01, 2006

Column

0

0

Hospitals don't want straight-up advertising. If a branded program is going to be integrated into a health-education or health-services platform that's offered directly to a patient's room, it needs to have objective value.